{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:43:49Z","timestamp":1783471429740,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004773","name":"Henan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004773","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.biopha.2024.117548","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T09:53:31Z","timestamp":1729072411000},"page":"117548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Synaptic vesicle protein 2-targeted doxorubicin-loaded liposome for effective neuroblastoma therapy"],"prefix":"10.1016","volume":"180","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyuan","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxu","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghui","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiafu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2024.117548_bib1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/med.21750","article-title":"Molecular targeting therapies for neuroblastoma: progress and challenges","volume":"41","author":"Zafar","year":"2021","journal-title":"Med. Res. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2024.117548_bib2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report","volume":"27","author":"Cohn","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"7749","key":"10.1016\/j.biopha.2024.117548_bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41586-019-1030-9","article-title":"Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase","volume":"567","author":"Herold","year":"2019","journal-title":"Nature"},{"issue":"7215","key":"10.1016\/j.biopha.2024.117548_bib4","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nature07399","article-title":"Oncogenic mutations of ALK kinase in neuroblastoma","volume":"455","author":"Chen","year":"2008","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2024.117548_bib5","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1038\/s41467-024-47945-7","article-title":"A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations","volume":"15","author":"Saldana-Guerrero","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2024.117548_bib6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10555-020-09843-4","article-title":"Genetic predisposition and chromosome instability in neuroblastoma","volume":"39","author":"Tonini","year":"2020","journal-title":"Cancer Metastas Rev."},{"issue":"571","key":"10.1016\/j.biopha.2024.117548_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd6169","article-title":"Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma","volume":"12","author":"Straathof","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.biopha.2024.117548_bib8","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.3390\/cimb46040200","article-title":"Revisiting Neuroblastoma: Nrf2, NF-kappaB and Phox2B as a Promising Network in Neuroblastoma","volume":"46","author":"Peggion","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"issue":"11","key":"10.1016\/j.biopha.2024.117548_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112809","article-title":"Connectivity map analysis indicates PI3K\/Akt\/mTOR inhibitors as potential anti-hypoxia drugs in neuroblastoma","volume":"13","author":"Uva","year":"2021","journal-title":"Cancers"},{"issue":"21","key":"10.1016\/j.biopha.2024.117548_bib10","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1158\/0008-5472.CAN-18-1045","article-title":"RAS-MAPK pathway-driven tumor progression is associated with loss of CIC and other genomic aberrations in neuroblastoma","volume":"78","author":"Eleveld","year":"2018","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2024.117548_bib11","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1002\/cncr.11797","article-title":"A phase II study of topotecan with vincristine and doxorubicin in children with recurrent\/refractory neuroblastoma","volume":"98","author":"Garaventa","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2024.117548_bib12","doi-asserted-by":"crossref","DOI":"10.2196\/27898","article-title":"Cardiovascular health status and genetic risk in survivors of childhood neuroblastoma and nephroblastoma treated with Doxorubicin: protocol of the pharmacogenetic part of the LESS-Anthra cross-sectional cohort study","volume":"11","author":"Zolk","year":"2022","journal-title":"JMIR Res. Protoc."},{"issue":"4","key":"10.1016\/j.biopha.2024.117548_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cells12040659","article-title":"Doxorubicin-an agent with multiple mechanisms of anticancer activity","volume":"12","author":"Kciuk","year":"2023","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.biopha.2024.117548_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","article-title":"Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems","volume":"65","author":"Tacar","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117548_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030893","article-title":"Recent preclinical and clinical progress in liposomal Doxorubicin","volume":"15","author":"Aloss","year":"2023","journal-title":"Pharmaceutics"},{"issue":"33","key":"10.1016\/j.biopha.2024.117548_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202203949","article-title":"Therapeutic nanocarriers inhibit chemotherapy-induced breast cancer metastasis","volume":"9","author":"Li","year":"2022","journal-title":"Adv. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2024.117548_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13205-020-2144-3","article-title":"Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications","volume":"10","author":"Khan","year":"2020","journal-title":"3 Biotech"},{"issue":"1","key":"10.1016\/j.biopha.2024.117548_bib18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-021-01096-0","article-title":"Nanomaterials for cancer therapy: current progress and perspectives","volume":"14","author":"Cheng","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117548_bib19","doi-asserted-by":"crossref","DOI":"10.4172\/2157-7439.1000519","article-title":"Advances in delivery systems for doxorubicin","volume":"9","author":"Zhao","year":"2018","journal-title":"J. Nanomed. Nanotechnol."},{"key":"10.1016\/j.biopha.2024.117548_bib20","first-page":"18","article-title":"Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors","volume":"5","author":"Bansal","year":"2019","journal-title":"Cardiooncology"},{"issue":"1","key":"10.1016\/j.biopha.2024.117548_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s11658-020-00243-8","article-title":"Differentiation of two human neuroblastoma cell lines alters SV2 expression patterns","volume":"26","author":"Lekholm","year":"2021","journal-title":"Cell Mol. Biol. Lett."},{"issue":"3","key":"10.1016\/j.biopha.2024.117548_bib22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12022-019-09584-3","article-title":"Synaptic vesicle protein 2 and vesicular monoamine transporter 1 and 2 ARe Expressed in Neuroblastoma","volume":"30","author":"Georgantzi","year":"2019","journal-title":"Endocr. Pathol."},{"issue":"5773","key":"10.1016\/j.biopha.2024.117548_bib23","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1123654","article-title":"SV2 is the protein receptor for botulinum neurotoxin A","volume":"312","author":"Dong","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.biopha.2024.117548_bib24","doi-asserted-by":"crossref","first-page":"44474","DOI":"10.1038\/srep44474","article-title":"Neuronal entry and high neurotoxicity of botulinum neurotoxin A require its N-terminal binding sub-domain","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2024.117548_bib25","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.febslet.2006.02.074","article-title":"The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves","volume":"580","author":"Mahrhold","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biopha.2024.117548_bib26","doi-asserted-by":"crossref","first-page":"1239592","DOI":"10.3389\/fimmu.2023.1239592","article-title":"Myeloid Vamp3 deletion attenuates CFA-induced inflammation and pain in mice via ameliorating macrophage infiltration and inflammatory cytokine production","volume":"14","author":"Dai","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117548_bib27","first-page":"1","article-title":"Role of SNARE proteins in tumourigenesis and their potential as targets for novel anti-cancer therapeutics","volume":"1856","author":"Meng","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2024.117548_bib28","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1146\/annurev-biochem-013118-111654","article-title":"Botulinum and Tetanus Neurotoxins","volume":"88","author":"Dong","year":"2019","journal-title":"Annu. Rev. Biochem"},{"issue":"1","key":"10.1016\/j.biopha.2024.117548_bib29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1042\/BJ20120100","article-title":"Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B","volume":"444","author":"Wang","year":"2012","journal-title":"Biochem J."},{"issue":"1","key":"10.1016\/j.biopha.2024.117548_bib30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/bit.24605","article-title":"Stable, high-affinity streptavidin monomer for protein labeling and monovalent biotin detection","volume":"110","author":"Lim","year":"2013","journal-title":"Biotechnol. Bioeng."},{"issue":"24","key":"10.1016\/j.biopha.2024.117548_bib31","doi-asserted-by":"crossref","first-page":"23225","DOI":"10.1074\/jbc.M501733200","article-title":"Engineering soluble monomeric streptavidin with reversible biotin binding capability","volume":"280","author":"Wu","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2024.117548_bib32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pep.2005.01.016","article-title":"Protein production by auto-induction in high density shaking cultures","volume":"41","author":"Studier","year":"2005","journal-title":"Protein Expr. Purif."},{"issue":"1","key":"10.1016\/j.biopha.2024.117548_bib33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jconrel.2008.09.008","article-title":"In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: involvement of cytotoxic effect on vascular endothelial cells","volume":"133","author":"Ogawara","year":"2009","journal-title":"J. Contr. Release"},{"issue":"1-2","key":"10.1016\/j.biopha.2024.117548_bib34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ijpharm.2008.03.025","article-title":"Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors","volume":"359","author":"Ogawara","year":"2008","journal-title":"Int J. Pharm."},{"issue":"51","key":"10.1016\/j.biopha.2024.117548_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201803717","article-title":"Effective and targeted human orthotopic glioblastoma xenograft therapy via a multifunctional biomimetic nanomedicine","volume":"30","author":"Zou","year":"2018","journal-title":"Adv. Mater."},{"issue":"3","key":"10.1016\/j.biopha.2024.117548_bib36","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice","volume":"24","author":"Tomayko","year":"1989","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117548_bib37","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0031-9384(01)00530-3","article-title":"The EthoVision video tracking system--a tool for behavioral phenotyping of transgenic mice.","volume":"73","author":"Spink","year":"2001","journal-title":"Physiol. Behav."},{"issue":"2","key":"10.1016\/j.biopha.2024.117548_bib38","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40265-021-01467-4","article-title":"Naxitamab: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.biopha.2024.117548_bib39","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-015-0399-5","article-title":"Dinutuximab: first global approval","volume":"75","author":"Dhillon","year":"2015","journal-title":"Drugs"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224014343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224014343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:52:16Z","timestamp":1773967936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224014343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":39,"alternative-id":["S0753332224014343"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117548","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synaptic vesicle protein 2-targeted doxorubicin-loaded liposome for effective neuroblastoma therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117548","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117548"}}